Sanofi (SNY) has received Chinese regulatory approval for two rare hematology drugs, Qfitlia and Cablivi, significantly ...

Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseasesQfitlia, the first antithrombin-lowering therapy for hemophilia, ...

Sanofi secures China approvals for Qfitlia and Cablivi, expanding its rare hematology portfolio with new options for ...

Two bleeding disorder treatments for both chronic and acute conditions, Qfitlia and Cablivi, have been approved in China.

With Qfitlia and Cablivi, Sanofi reaches its fourth and fifth approvals in China this year, following Tzield for stage 2 type ...

Investing.com -- Sanofi has received approval for two bleeding disorder treatments in China, expanding its hematology portfolio in the country. The French pharmaceutical company announced Thursday ...

(RTTNews) - Sanofi (SNY) announced the National Medical Products Administration in China has approved two Sanofi medicines for rare hematologic diseases: Qfitlia or fitusiran for hemophilia and ...

At Sanofi, we are committed to supporting the aTTP community and the health care providers who treat them. As part of this commitment, we have launched the Sanofi Promise Warranty Program for Cablivi ...

The European Commission has approved Sanofi’s Cablivi, the first treatment for patients with the rare blood-clotting disorder, acquired thrombotic thrombocytopenic purpura (aTTP), which is also ...

Sanofi announced that the Food and Drug Administration (FDA) has approved Cablivi (caplacizumab-yhdp) for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP), in ...

Qfitlia, the first antithrombin-lowering therapy for hemophilia, can offer consistent protection with as few as six injections a year Cablivi, the first Nanobody medicine, targets ...